EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pediatric Craniofacial Osteosarcoma: The Milano Experience

Cristina Meazza iD, Francesca Parisi iD, Francesco Barretta, Giovanna Sironi, Olga Nigro iD, Carlo Morosi, Roberto Luksch iD, Marta Podda, Andrea Ferrari iD, Monica Terenziani iD, Filippo Spreafico iD, Michela Casanova und 15 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Cristina Meazza und 26 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Hauptthemen laut MEDLINE: Osteosarcoma, Skull Neoplasms, Neoplasm Recurrence, Local, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BIBLIOSAN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Craniofacial osteosarcoma (CFOS) is a rare tumor, typically affecting patients over 60, with a low incidence of metastasis at diagnosis as well as at relapse. Patients and methods This study analyzed patients treated for high‐grade CFOS at Fondazione IRCCS Istituto Nazionale dei Tumori between 1991 and 2021, focusing on histological characteristics, systemic and local treatment, and outcome.

Results

Eleven patients (7F/4M) were included, with a median age of 15 years. Eight patients had an unfavorable site of origin (maxilla, cranial fossae, skull), seven had an unfavorable histology (i.e., chondroblastic subtype), and four had a high‐grade tumor (G4). Five had both unfavorable histology and primary tumor site, and three of the five a G4 tumor. Chemotherapy (MAP or MAPI regimen) was administered to all, with five receiving neoadjuvant treatment. Surgery was performed on all, achieving clear margins in eight patients (four of them had received neoadjuvant CT). Two of three patients with R1 surgery received adjuvant radiotherapy (RT) and are still alive and disease‐free. Three patients died of relapse, all with unfavorable primary tumor sites, G4 tumors, and two with unfavorable histology; one patient with positive margins had not received RT. At a median follow‐up of 65.8 months, 5‐year PFS was 100% for favorable tumor sites, 50% for unfavorable sites, and 85% for G3 tumors compared to 25% for G4 tumors.

Conclusion

Unfavorable tumor sites and G4 tumors may be indicative of a worse prognosis, especially as all relapsed patients had both. RT should be considered for R1 surgery. Due to the disease's rarity and complexity, specialized centers with expertise in head and neck sarcoma are essential for managing these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaSkull NeoplasmsNeoplasm Recurrence, LocalBone NeoplasmsHumansMaleFemaleAdolescentChildFollow-Up StudiesPrognosisSurvival RateRetrospective StudiesChild, PreschoolNeoadjuvant TherapyYoung AdultCombined Modality Therapy

Stichwörter der Autor:innen

chemotherapygradinghistologic subtypeosteosarcomaprimary tumor siteradiotherapysequelaesurgery

Autor:innen und Institutionen

  • Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • U.O.C. Oncologia Pediatrica IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
  • Pathology Department, Azienda Socio Sanitaria Territoriale Gaetano Pini, Milano, Italy.

ORCID-Profile: Cristina Meazza, Francesca Parisi, Olga Nigro, Roberto Luksch, Andrea Ferrari, Monica Terenziani, Filippo Spreafico, Elisabetta Schiavello, Luca Bergamaschi, Giovanna Gattuso, Valeria Colombo, Maura Massimino

Förderung

  • BIBLIOSAN

Zitieren

APA

Meazza, C., Parisi, F., Barretta, F., Sironi, G., Nigro, O., Morosi, C., Luksch, R., Podda, M., Ferrari, A., Terenziani, M., Spreafico, F., Casanova, M., Biassoni, V., Schiavello, E., Parafioriti, A., Collini, P., Chiaravalli, S., Puma, N., Bergamaschi, L., …, & Massimino, M. (2025). Pediatric Craniofacial Osteosarcoma: The Milano Experience. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31808

Vancouver

Meazza C, Parisi F, Barretta F, Sironi G, Nigro O, Morosi C, et al. Pediatric Craniofacial Osteosarcoma: The Milano Experience. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31808

BibTeX
@article{Meazza2025,
  author = {Meazza, Cristina and Parisi, Francesca and Barretta, Francesco and Sironi, Giovanna and Nigro, Olga and Morosi, Carlo and Luksch, Roberto and Podda, Marta and Ferrari, Andrea and Terenziani, Monica and Spreafico, Filippo and Casanova, Michela and Biassoni, Veronica and Schiavello, Elisabetta and Parafioriti, Antonina and Collini, Paola and Chiaravalli, Stefano and Puma, Nadia and Bergamaschi, Luca and Gattuso, Giovanna and Colombo, Valeria and Vennarini, Sabina and Pecori, Emilia and Guzzo, Marco and Colombo, Sarah and Trovò, Arianna and Massimino, Maura},
  title = {Pediatric Craniofacial Osteosarcoma: The Milano Experience},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31808}
}
Kostenlos starten →